Is Less Really More?: Determining the Efficacy and Advantages of Low Dose Chemotherapy by Toews, Natalie
Running head: LOW DOSE CHEMOTHERAPY 1 
 
 
 
 
 
 
 
 
 
 
 
Is Less Really More?: Determining the Efficacy and Advantages of Low Dose 
Chemotherapy 
 
 
 
 
 
 
 
 
 
Natalie Toews 
 
 
 
 
 
 
 
 
 
A Senior Thesis submitted in partial fulfillment 
of the requirements for graduation 
in the Honors Program 
Liberty University 
Spring 2012 
  
LOW DOSE CHEMOTHERAPY 2 
Acceptance of Senior Honors Thesis 
 
This Senior Honors Thesis is accepted in partial 
fulfillment of the requirements for graduation from the 
Honors Program of Liberty University. 
 
 
 
 
 
______________________________ 
Deanna Britt, Ph.D. 
Thesis Chair 
 
 
      
 
 
 
______________________________ 
David Duby, Ph.D. 
Committee Member 
 
 
     
 
______________________________ 
Teresa Page, F.N.P. 
Committee Member 
 
 
         
 
 
 
______________________________ 
Brenda Ayres, Ph.D. 
Honors Director 
 
 
 
 
 
 
______________________________ 
Date 
  
 
 
 
LOW DOSE CHEMOTHERAPY 3 
Abstract 
Chemotherapy is the preferred treatment for patients with breast cancer nationwide; 
however, the dosage and duration of this treatment have come under recent scrutiny. The 
efficacy of high dose chemotherapy is many times inadequate, and the adverse physical 
effects resulting from this regimen have a negative holistic impact on the patients. Studies 
suggest that low dose chemotherapy, through antiangiogenesis, affects the spread of 
breast cancer carcinomas and may produce less harmful side effects in relation to the 
heart, brain, and eyes. Thus, oncological research proposes that a low dose regimen 
improves the patient’s quality of life and may be an effective regimen to treat breast 
cancer, simultaneously. Chemotherapy administered in low doses, coupled with 
innovative treatments such as insulin potentiation, may prove to be a regimen able to 
weaken breast malignancies without debilitating the patient’s daily functioning.  
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Is Less Really More?: Determining the Efficacy and Advantages of Low Dose 
Chemotherapy 
 As Breast Cancer percentages continue to escalate, the search for a cure continues 
to gain ground. Breast cancer is the most common cancer among women worldwide, and 
comprises 16% of female cancers (Pinto & Azambuja, 2011). Although scientists around 
the world strive to cure breast cancer, and cancer in general, it is important that research 
developments in alternative oncological treatments are given consideration. The search 
for a cure is important, and the vital nature surrounding a cure for cancer should not be 
discouraged. However, current treatment for breast cancer, chemotherapy more 
specifically, should perhaps draw some of the intention solely focused on a cure and be 
viewed with a scrutinizing eye concerning the duration, the liberality of use, and the 
negative effects of the treatment.  
 Chemotherapy has played the lead role in treating breast cancer since its induction. 
Physicians have advised women struggling against this illness to undergo the extensive, 
and often detrimental, effects of high dose chemotherapy. This regimen has somewhat 
been deemed the “holy grail” of breast cancer treatment, as well as the first line of 
defense. However, the physical implications and efficacy of the dosage should be 
considered before undergoing a traumatic treatment. The benefits of chemotherapy 
should not be overlooked; however, the extent to which chemotherapy treatments are 
performed should be closely examined by both the physician and the patient. A serious 
regard for the symptoms, melded with a passion and heart for treatment and the best 
possible outcome for a patient, should take precedence over a “the more the better” 
medical outlook. Although modern scientists unswervingly digress to high dose 
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chemotherapy for breast cancer patients, a conservative mindset regarding the duration 
of treatment in support of low dose therapy, and a realistic perspective of 
chemotherapy’s efficacy, may warrant further study.  
Background  
Breast Cancer Pathophysiology 
Breast Cancer is the most common malignancy in women worldwide except for 
skin cancer and is second only to lung cancer as the leading cause of cancer related death 
in women. Patients diagnosed with breast cancer that showing no axillary node 
involvement have a 98% five-year-survival rate. In contrast, there is only a 6% 5-year-
survival rate for those with advanced stage breast cancer that has metastasized to distant 
sites (Buchner, Dirksen, Heitkemper, Lewis, & O’Brien; 2009). As this disease continues 
to impact more lives each day, the quest for an effective treatment has impelled scientists 
worldwide to optimize treatment. 
Etiology. Cancer encompasses a variety of diseases of multiple causes that can 
arise in any cell of the body capable of evading regulatory controls over proliferation and 
differentiation. Normally the processes of cell division and proliferation are activated 
only when the body has a need for more cells, such as increased white blood cell count to 
fight an infection. Normal cells also respect the boundaries and territory of the 
surrounding cells in a phenomenon called contact inhibition. Cancer cells are 
characterized by a loss of contact inhibition; they “have no regard for cellular boundaries 
and will grow on top of one another and also on top of or between normal cells” 
(Buchner et al., 2009, p. 273). This lack of boundaries results in the proliferation of 
cancer that far exceeds healthy cell production. 
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Cancer progresses through three stages in an orderly and maliciously efficient 
manner: initiation, promotion, and progression. In initiation there is a mutation in the 
cell’s genetic structure resulting from an inherited mutation or an environmental exposure 
to radiation, chemicals, or a viral agent. This altered cell has the ability to develop into a 
group of mutated neoplastic cells. These cells may continue to multiply and form a 
tumor, or they undergo apoptosis and are destroyed. Promotion, the next stage of cancer, 
is characterized by the “reversible proliferation of the altered cells” (Buchner et al., 2009, 
p. 276). Promoting agents, such as cigarette smoking, obesity, dietary fat, and alcohol 
consumption, are modifiable factors that increase the chances for the development of 
cancer by providing an environment in the body that potentiates cancer growth. The 
progression stage marks the final phase of cancer development. During progression, there 
is increasing growth of the tumor, increased invasiveness, and the metastasis of the 
cancer (Buchner et al.).  
Epidemiology. Although the exact cause for cancer is unknown, it has been 
linked with many chemical, environmental, genetic, immunologic and viral origins. Most 
cancer cells exhibit a characteristic called genetic instability, considered the hallmark of 
cancer. Uncontained mutations in normal cells are rare because of the multiple built in 
mechanisms that prevent unwanted changes. Scientists characterize genetic instability as 
mutations stemming from aneuploidy (the loss or gain of chromosomes), 
intrachromosomal instability, repetitive sequences of short DNA, and point mutations 
(Buchner et al., 2009). 
Genetic alterations in tumor suppressor genes, such as the BRCA-1 gene, have 
been linked with an increased risk of developing breast cancer due to heredity. Slight 
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changes in BRCA-1 inhibit its ability to stop tumor proliferation, and those with these 
mutations have a 40% to 80% lifetime chance of developing cancer (Buchner et al., 
2009). Changes in the BRCA-2 gene, located on chromosome 11, evidently increase the 
risk of breast cancer as well. As many as 1 in 200 to 400 women in the United States may 
carry the BRCA-1 or BRCA-2 abnormalities (Buchner et al., 2009). These genetic 
modifications show that, despite a conscious avoidance of all modifiable risk factors, 
many women who develop this disease were already endangered since birth simply 
because of their genetic makeup. Thus, the maintenance of their quality of life through 
administration of low dose chemotherapy could significantly influence the treatment of 
the cancer and the self-efficacy of the patient. 
The natural history of breast cancer fluctuates considerably from patient to 
patient, and the rate of the growth can range from slow to rapid. Tumor differentiation, 
estrogen and progesterone sensitivity, and the overexpression of human epidermal growth 
factor receptor 2 all affect cancer prognosis. Recurrence, or the advancement of the 
cancer, is considered the primary complication of breast cancer. Metastasis may be local 
or regional (confined to the soft tissue, mastectomy site, and axillary nodes surrounding 
the primary tumor), or they may be distant (involving the lung, brain, bone, and liver). 
Patients with a higher percentage of proliferative cells in the S phase of the cell cycle 
have a greater risk for recurrence and cancer deaths (Buchner et al., 2009). Low dose 
chemotherapy may take precedence as the vital treatment for breast cancer patients 
because it diminishes recurrence and halts the progression of cancer cell transportation 
from local regions to distant sites.  
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Chemotherapy  
 Breast cancer tumors respond to chemotherapy more than most malignancies. 
Physicians administer chemotherapeutic agents in combination treatments that allow the 
individual effects of select cytotoxic drugs to treat the cancer simultaneously. 
Cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, and epirubicin are the 
most prominent chemotherapy drugs used in breast cancer management, and are the 
deliberated prototypes in most major studies concerning chemotherapy usefulness 
(Matfin & Port, 2009). 
 Cancer chemotherapeutic drugs exert their effects through multiple means 
primarily on the cellular level. Their lethal capabilities rely on their ability to target the 
growth and replication of cancer cells by “disrupting the production of essential enzymes; 
inhibiting DNA, RNA, and protein synthesis; and preventing cell mitosis” (Matfin & 
Port, 2009, p. 183). Cytotoxic drugs treat tumors most effectively because they kill 
rapidly dividing cells. Chemotherapy efficiency is measured by the percentage of tumor 
cells killed, rather than the absolute number of cells destroyed, in a process termed 
“exponential killing” (Matfin & Port, p. 183). 
 Cellular resistance to cancer chemotherapy poses a major problem in breast 
cancer treatment. Acquired resistance to cytotoxic agents can be highly specific. This 
results from genetic changes in the tumor. Experimentally, a multi-drug resistant 
phenomenon has been observed. Scientists believe the presence of drug resistance results 
from an increase in the number of transporter genes involved in the intracellular influx of 
chemotherapeutic agents (Matfin & Port, 2009).   
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 Chemotherapy drugs are divided into varying subgroups depending on their 
mechanism of action. Cell specific drugs exert their lethal action during particular phases 
of the cell cycle. Methotrexate, an antimetabolite, interferes with the DNA synthesis that 
takes place during the S phase of the cell cycle. It disrupts DNA synthesis progression, 
causing misincorporation into DNA, and alters the function of biosynthetic enzymes. 
Alkylating agents, such as cyclophosphamide and ifosphamide, are not specific to a 
certain cycle, and are therefore capable of impeding DNA synthesis when cells are 
dividing and when they are at rest. The disadvantage of these agents results from their 
dose related toxicity that occurs in rapidly proliferating cells of the bone marrow, 
reproductive tissues, and gastrointestinal tract (Matfin & Port, 2009). 
The Efficacy of Low Dose Chemotherapy 
 In a nation that holds a “the more the better” outlook on medicine, it can be 
difficult to persuade a patient that in some instances, less is more.  Patients receiving high 
dose regimens of chemotherapy find that they succumb to the destructive symptoms of 
their chemotherapy in order to observe the benefits of their treatment.  When given in low 
doses over extended periods of time, chemotherapeutic agents effectively combat 
cancerous tumors. Further knowledge of antiangiogenic mechanisms, as well as its 
efficacy concerning vascular endothelial growth factors, may make low dose 
chemotherapy an attractive alternative to high dose chemotherapeutic regimens 
(Albertsson, Lennernas & Norrby, 2009; Andre, Kavallaris & Pasquier, 2010).  
Antiangiogenic Effects 
 According to an analysis published in Cancer Biology & Therapy, metronomic 
chemotherapy is defined as, “the chronic administration of chemotherapy at low doses 
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without toxicity or with only minimal toxicity -- a frequent schedule of administration at 
close regular intervals and without prolonged drug-free breaks” (Giuseppe, Schiavon, 
Silletta, Vincenzi & Santini, 2007, p. 183). Angiogenesis refers to the process of new 
blood vessels branching from existing vessels in order to increase the vasculature and 
promote growth in the cancerous tumor.  Conventional MTD therapy primarily disturbs 
the production of rapidly proliferating cancer cells in contrast to metronomic drug 
administration, which targets stable microvessel cells involved in angiogenesis. The 
normal endothelial cells produce at a much slower rate, which reduces the risk of drug 
resistance, in turn making the drug regimen more affective. Scientific support of 
metronomic administration reasons that low dose chemotherapy proactively affects the 
spread of cancer by focusing on the cells of the microvasculature that have greater 
sensitivity compared to the neoplastic cells of a proliferative tumor (Albertsson, et al., 
2009; Andre et al., 2010). 
A breast cancer tumor becomes increasingly dangerous as angiogenesis causes 
microvasculature stemming from the malignancy to proliferate throughout the body. 
Breast malignancies are fortified through glucose stores in the blood (Albertsson, et al., 
2009). In fact, many tumors create their own insulin in order to draw the glucose into the 
cancer cells. An increase in angiogenesis causes a surge in the circulation of blood that 
feeds the tumor, leading to the exponential growth of the cancerous mass (Kerbel, 2007).  
The vasculature also acts as a prime pathway for the transportation of seeding 
cancer cells to other areas of the body, leading to metastasis of the cancer. The migration 
of the cancer cells to the lymph nodes, and from thence to the lymph and other vital 
organs and tissues, depends on the angiogenesis of the prime and successive tumors 
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(Cronin, 2010). Thus, the fight against cancer must often start at the tumor’s vasculature 
instead of the tumor itself. In order to destruct the malignancy at its foundation, its 
nutrient supply and means of metastasis must be obliterated. The philosophy motivating 
research regarding the administration of metronomic chemotherapy stems from its ability 
to halt the mobilization of endothelial cells from the bone marrow in order to arrest 
angiogenesis (Cronin, 2010; Albertsson, et al., 2009). In order to combat cancer 
expansion, studies suggest that low dose chemotherapeutic agents have an antiangiogenic 
capacity that  
Browder et al. played a pivotal role in the development of breast cancer treatment 
when they first examined the effectiveness of low dose chemotherapy and its 
antiangiogenic capabilities. Tumor-bearing mice that were given cyclophosphamide, a 
standard chemotherapeutic drug for breast cancer, at their maximum tolerated dose 
required 3 weeks to allow for bone marrow recovery before their next dose (Browder, 
Butterfield & Kraling, 2000). The prolonged rest period over several weeks allowed the 
apoptosis, or cell death, that had taken to place in the tumor to be repaired. Hence, the 
tumor was only superficially affected and the high dose of cyclophosphamide minimally 
combated the cancer malignancy. When the same drug was administered to the mice at a 
rate of once a week, the antiangiogenic effects remained. The tumor cells did not have the 
chance to repair because of the continuous influx of cytotoxic therapy, and the mice 
withstood the toxic effects of the drug because they were only given one third of the 
maximum tolerated dose (MTD). This provocative study concluded that the focus of 
cancer treatment may need to shift from a purely transient cytotoxic regimen, to a more 
conservative antiangiogenic regimen that limits chemotherapy resistance (Browder et al.).  
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This research resurfaced in the sphere on oncological research, and has been cited in 
current studies that support a metronomic dosage of drugs in order to combat tumor 
angiogenesis (Kerbel, 2007; Zelnak & ORegan, 2007; Albertsson, et al., 2009; Andre et 
al., 2010) 
 Research continues to delve into the low dose chemotherapy regimen stipulated by 
Browder et al. more than ten years ago. Since the introduction of cytotoxic 
chemotherapeutic agents, high dose chemotherapy has remained the mainstay of cancer 
treatment; however, an antiangiogenic, low-toxicity preference may breathe new life into 
breast cancer research. The existence of fibrocystic lesions with a higher vascular density 
has been linked with increased risk of breast cancer and a microvessel density that is 
much more sensitive to antiangiogenic treatment. A study of 49 primary breast 
carcinomas, as well as a blind study of 165 patients with invasive breast cancer, showed 
that “an elevated tumor microvessel density was associated with poorer overall and 
relapse-free survival in all patients” (Zelnak & ORegan, 2007, p. 210). The evidence 
linking microvasculature to angiogenic chemotherapy treatment sparked further research 
into low dose chemotherapy efficacy by Zelnak and ORegan. Metronomic therapy using 
low doses of oral methotrexate and cyclophosphamide in patients with metastatic breast 
cancer demonstrated an overall response rate of 19%; the overall clinical benefit, which 
took into account complete response, partial response, and those with stable disease, 
indicated that 32% or patients given low doses of the same chemotherapy agents had a 
statistically significant improvement in disease treatment (Zelnak & ORegan). 
 In an article published in Nature Reviews Clinical Oncology it was noted that the 
administration of minimally toxic doses of chemotherapeutic agents “inhibits tumor 
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growth primarily through anti-angiogenic mechanisms while significantly reducing 
undesirable toxic side effects” (Andre et al., 2010, p. 456). A breast malignancy that is 
treated with a continual low dose regimen is not given time to recuperate between doses. 
The chemotherapeutic agents act as a consistent force against the proliferation and 
metastasis of the tumor, and the cancer is unable to combat the opposition (Andre et al.; 
Munoz, 2006).  
 High dose chemotherapy, as opposed to metronomic treatment, often elicits future 
resistance to the cytotoxic drugs that were administered. Andre et al. (2010) proposed 
that patients who had undergone this regimen were minimally affected by their 
chemotherapy at a later time because their bodies were able to produce antibodies against 
their chemotherapy during the weeks set apart for their recovery between doses. 
Unfortunately, the patients required a rest in between doses in order to physically 
recuperate, but the time period was found to be detrimental to the response of their breast 
malignancy to their chemotherapy. Each dose patients were given using a transient, high-
dose approach contributed progressively more to their chemotherapy resistance, and 
progressively less to their fight against cancer (Andre et al., 2010). 
Vascular Endothelial Growth Factor  
 The case for metronomic therapy is taken a step further when one examines an 
angiogenic polypeptide called vascular endothelial growth factor (VEGF). A variety of 
human malignancies, including breast, lung, gastrointestinal tract and brain tumors, 
exhibit this factor (Buchner et al., 2009). The “increased expression of VEGF has been 
shown to be of prognostic significance in both node-negative and node-positive breast 
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carcinoma, with higher VEGF expression associated with worse overall survival,” and is 
an indicator of tumor vasculature growth potential (Donovan & Kummar, 2006, p. 9).   
The production of VEGF is directly correlated to the angiogenesis and metastasis 
of breast cancer, while anti-VEGF substances are equally indicative of tumor inhibition. 
The importance of this polypeptide lies in the fact that the ability of a chemotherapeutic 
agent to oppose its effects has become a marked indicator of cancer remission. Patients 
with disseminated breast cancer have been noted to show higher serum VEGF 
concentrations in comparison to those with localized cancer. The presence of VGEF and 
its relationship with breast cancer may indicate the growth factor’s specific role in 
angiogenesis and breast cancer development (Salter & Miller, 2007). Normal physiologic 
conditions exhibit a clear balance between angiogenic mediators and antiangiogenic 
substances. When the body is faced with a hypoxic or inflammatory stimulus, such as a 
malignant mass, “the balance is ‘tipped’ in favor of angiogenesis, and the switch 
promoting new vessel growth and recruitment is activated” (Salter & Miller, 2007, p. 
518). 
 VEGF is responsible for endothelial cell activation that is necessary for the 
formation of microvasculature. The inhibition of this polypeptide is vital to decreasing 
angiogenesis and its role in breast cancer metastasis. VEGF causes “upregulation of 
integrin expression and changes in the cell cytoskeleton” (Donovan & Kummar, 2006, p. 
10). The intricate, cellular process facilitates the movement and development of 
endothelial cells and the formation of new blood vessels. If chemotherapeutic drugs can 
act as a barrier to the production of VEGF, and thus stop angiogenesis at its roots, then 
their efficacy is greatly increased (Scharovsky, Mainetti & Rozados, 2009). 
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Research regarding the ability of low dose chemotherapy to restrict the formation 
of endothelial growth via VEGF was first performed, and published in the Annals of 
Oncology. Colleoni et al. studied 63 patients with metastatic breast cancer that had been 
previously treated with various chemotherapeutic agents. These patients had been given 
chemotherapeutic drugs previously, but had developed resistance to the cytotoxicity of 
their prescribed treatments because their chemotherapy was apportioned to them in high 
doses. The median serum VGEF level baseline at the initiation of the study was 
calculated at 315 pg/ml, and after 6 months the VGEF levels had decreased to a 
significantly lower level of 195 pg/ml. Colleoni et al. concluded that low doses of 
cyclophosphamide and methotrexate “demonstrated significant efficacy in pre-treated 
metastatic breast cancer” (Colleoni et al., 2002, p. 78).  The study also indicated that a 
low dose chemotherapeutic regimen counteracts malignancy over time by inhibiting 
tumor proliferation by decreasing serum levels of VGEF (Scharovsky, Mainetti & 
Rozados, 2009). The groundbreaking research performed by Colleoni et al. has sparked 
research that further supports the VEGF role in therapeutic philosophy, and may lead to 
the implementation of this therapy in future oncological treatment. 
Quality of Life 
 Patients with breast cancer are often seen as a physical diagnosis, a metastasizing 
tumor, or a medical challenge to many physicians. In reality, oncologists must recognize 
their humanity primarily, and then their disease, and all facets of their personhood should 
be of upmost importance. In order to accomplish holistic care, the quality of life of the 
patient must take precedence along with their physical healing. Fedele et al. stated this 
concept perfectly in their study found in the European Journal of Cancer:   
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Metastatic breast cancer (MBC) is a highly heterogeneous disease, and decisions 
regarding its treatment must be driven by multiple considerations, including not 
only the clinical and biological parameters of the case but also patient preferences. 
Despite recent advances in our understanding of the biology of MBC and in the 
development of new types of therapy, the disease remains incurable. The goals of 
treatment are, therefore, palliative – prolonged survival, control of symptoms, 
improvement or maintenance of quality of life – all of which require a careful 
balance between treatment efficacy and toxicity (Fedele, Marino, Orlando, 
Schiavone, Nacci, Sponziello, Rizzo et al., 2011). 
         It has long been thought that in order to reap the benefits of chemotherapy one’s 
quality of life must also suffer. The origins of chemotherapy were derived out of a 
mentality that the greatest amount of cytotoxic drugs tolerated by the patient would 
produce the greatest antitumor result. Chemotherapy has been pumped liberally into 
women fighting breast cancer for decades and has left society with the standard mental 
image of a woman in the midst of her battle: suffering from significant alopecia, ever-
present fatigue, unable to participate in life’s routines, and frail. In essence, the public has 
come to define chemotherapy as a drug that sustains the duration of life but saps the 
patient’s ability to thrive. If low dose chemotherapy is to take its place amongst the 
mainstream treatments for breast cancer, patients may question its effectiveness: Is it 
really possible that cancer can be fought without completely dismantling the activities of 
daily life? 
          Levels of toxicity may measure chemotherapy benefits on the cellular level, but 
surveys concerning the health related quality of life take into account the effects of the 
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breast cancer on a woman’s well-being (Richardson, Wang, Hartzema, & Wagner, 2007). 
In fact, if the quality of life drops significantly, the affected breast cancer patient may 
choose to discontinue treatment. When given the chance to live longer while suffering the 
repercussions of cytotoxic treatment or decrease one’s lifespan but live free of the side 
effects, the patient will often choose the latter. If the side effects of chemotherapeutic 
drugs become so severe that the patient drops out of treatment, then the utility of 
chemotherapy is greatly compromised (Richardson et al.).  
           If further research illuminates anti-cancer success with a low dose chemotherapy 
regimen, a solution to women who will to experience the anticancer benefits of 
chemotherapy, without losing their quality of life in the process, may be on the horizon. 
Decreased doses of chemotherapeutic agents produce less harmful side effects without 
losing efficacy, making them an advantageous choice for oncologists nationwide. 
Physical and Symptomatic Advantages of Low Dose Chemotherapy 
Women battling breast cancer may believe that the extent of their trials resulting 
from their therapy is the loss of their hair and nausea. However, the potential for a more 
severe illness or symptoms to arise from the effects of chemotherapeutic agents is a grave 
reality that must be considered before entering into a chemotherapy regimen. The quality 
of life for breast cancer patients is already compromised due to neutropenic tendencies 
and a lingering muscle weakness. When high dosages chemotherapy are added to the 
quality of life equation, severe cardiac, cognitive, and ocular effects have been noted 
(Azim, Azambuja, Colozza, Bines & Piccart, 2011; Dutta, 2011; Schmid, Kornek, 
Scheithauer & Binder, 2006). 
Cardiotoxicity 
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 The effects of aggressive chemotherapy using the breast cancer patient’s 
maximum tolerated dose suggest a trend between increased dosage and damage to cardiac 
health. For many breast cancer patients, the diagnosis of cancer is not their first medical 
complication. In today’s modern society, where heart disease has grown to play the major 
role in mortality amongst the American public, it is vital that oncologists subject their 
patients to as little cardiac toxicity as possible. Low dose chemotherapy is able to target 
the patient’s carcinoma without leading to proliferative cardiac cell death.  
 Anthracycline-based regimens using doxorubicin or epirubicin have become 
widely used cytotoxic drugs in the past thirty years. These agents carry a significant risk 
for cardiac toxicity, which increases directly with the administration of transitory high 
dose of chemotherapy using a MTD regimen (Azim et al., 2011; Matfin & Port, 2009). 
The elevated dose of cytotoxic drugs, more specifically those included from the 
arthracycline spectrum, correlated with an increase in cardiac injury. Free radicals 
derived from these toxic medications are believed to damage myocardial cells, but the 
symptoms of the damage often lie dormant for years following the immediate injury 
(Bird & Swain, 2008). Even though the effects of the aggressive chemotherapy are not 
always immediately diagnosed, the impact of the cardiac impairment can express itself 
years later as congestive heart failure. Azim et al. studied the likelihood of breast cancer 
patients acquiring congestive heart failure (CHF) in relation to chemotherapy dosages. 
They documented that patients who received cumulative doses not exceeding those used 
in standard regimens had an 8-year probability of acquiring CHF calculated at 0.37% 
compared with 4.97% probability for those who received higher doses (Azim et al.). 
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 In 2008, Clinical Cancer Research published a study that delved further into CHF 
and the prevalence of chemotherapeutic regimens that promoted the disease. For eight 
years, 85 breast cancer patients were given a cumulative dose of 600mg/m2 of epirubicin 
and were tracked alongside 65 patients who were administered a cumulative dose of 
300mg/m2 of epirubicin. The end results revealed that not one of the sixty-five patients 
given the lower dose acquired CHF, but 2% of those given the larger 600mg/m2 dose 
were diagnosed with the cardiac disease. Although 2% may seem like a small margin, in 
the scheme of the big picture that small percentage amounts to thousands of breast cancer 
patients diagnosed with heart failure. Epirubicin is neither an obscure chemotherapeutic 
drug, nor is it considered to be more harmful or toxic compared to other cytotoxic drugs 
(Bird & Swain, 2008). The effects of this study gave scientists heightened insight into 
cytotoxic regimens as a whole, and the significance the amount and duration of a drug 
given has on the heart compared to the drug itself.   
In those patients who had risk factors for cardiac complications in addition to 
their malignancy, such as old age, smoking, hypertension, mediastinal radiotherapy, and 
preexisting coronary artery disease; the harm that ensued high dose chemotherapy was 
even greater. Acute cardiac side effects of the high dose cytotoxic medications included 
left ventricular dysfunction, arrhythmias, pericarditis, and myocarditis (Bird & Swain, 
2008). 
 In addition to congestive heart failure, cardiomyopathy in general has also been 
linked with the ingestion of high doses of chemotherapeutic drugs. The connection 
between increased dosages of doxorubicin and damage to cardiac musculature is often 
apparent 2 to 3 days after the initiation of high dose therapy.  A patient may also present 
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with arrhythmias, conduction disorders, and acute pericarditis and myocarditis after 
undergoing an anthracycline-based regimen.  Instances of dose-dependent 
cardiomyopathy, secondary to cytotoxic medication ingestion, often lead to chronic 
debilitation of the patient’s cardiac health (Matfin & Port, 2009). 
The rise in dosage correlated diametrically to the percentages of those who 
developed CHF and/or suffered from a cardiac event. After supporting the existence of 
the aforementioned relationship, Expert Reviews (Yusuf, Ilias-Khan, & Durand, 2011) 
expanded on the specific ways the chemotherapeutic anthracycline-based regimen 
negatively affects the heart. Cytotoxic drugs lead to cardiomyopathy by disrupting 
myofilament protein synthesis, resulting in the necrosis of the cardiac cells inhibited by 
the resulting lack of cardiac proteins. These mechanisms have been linked with the 
swelling of the mitochondria and chromatin loss hours after the initial maximum tolerated 
dose. These microscopic changes present as cardiac remodeling and eventually lead to 
left ventricular systolic failure, diastolic dysfunction, and even mortality (Yusuf et al.). 
Chemotherapy Induced Cognitive Impairment 
 As breast cancer awareness has increased, so has the demand for research 
concerning the specifics of the illness. In an article found in the Journal of Cancer 
Research and Therapeutics, clinical neuropsychologist Varsha Dutta discussed the 
decrease in cognitive capabilities reported by women following chemotherapy called 
CICI, or chemotherapy-induced cognitive impairment. Terms such as “chemobrain” and 
“chemofog” have been coined to describe women who have reported experiencing 
increased difficulties with concentration or planning and loss of short-term memory. 
Chemotherapeutic drugs that induce an inflammatory cellular environment raise TNF 
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Alpha levels that have been shown to produce neuronal injury and disrupt brain 
metabolism because they target the nerve fibers that act as transmitters for electric signals 
in the brain (Dutta, 2011).  
The Journal of Pain and Symptom Management reported: “The incidence of long 
term CICI can affect a significant portion of cancer survivors, with an incident rate 
ranging from 16 to 75%,” and has been shown to progress for 2 to 10 years after its 
manifestation in some patients (Argyriou, Assimakopoulos, Iconomou, Giannakopoulou 
& Kalofonos, 2011, p. 127). This sheds light on the concept that the cognitive effects of 
high dose chemotherapy, be they serious or simply inconvenient, may endure for years, 
and the cessation of symptoms is not contingent on chemotherapy termination. 
The Journal of the National Cancer Institute found that those who received high 
dose chemotherapy had a statistically significant increased risk of cognitive impairment 
compared with those who did not undergo chemotherapy. However, low dose 
chemotherapy treatment was also included in the equation, and the same study showed a 
decreased risk for CICI in patients taking metronomic doses. In fact, that same selection 
of patients did not show a statistically significantly elevated risk compared with the 
control group comprised of healthy individuals who did not have breast cancer, and had 
no previous exposure to chemotherapeutic agents (Schagen, Muller, Boogerd, 
Mellenbergh & Van Dam, 2006, p.1743). It was concluded that the probability of a 
patient developing debilitated cognitive capabilities decreased when cytotoxic drugs were 
received in smaller increments on a more continual basis. 
In addition to brain matter as a whole, the hippocampus is also a target, due to its 
glucocorticoid receptors. Chemotherapeutic agents elevate glucocorticoids, which can 
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have “a detrimental effect in the form of heightened susceptibility to neurotoxic stress, 
obstructed neuronal growth, and increased cell death within the hippocampus” (Dutta, 
2011, p. 267). Simply stated, Dutta contends that increased doses of cytotoxic drugs 
induce a heightened stress response, causing the release of glucocorticoids, which in turn 
damages the hippocampus. The end result of this process is a decrease in functioning of 
the brain, and a symptomatic response shown as an inability to focus, or as a patient in 
the study stated, “vague forms of cloudiness that often comes in the way of daily 
planning of even routine chores” (Dutta, 2011, p.266). 
Optic Side Effects 
 (sentence erased) Vision is an imperative component in evaluating a breast cancer 
patient’s quality of life, and risk to one’s visual acuity can essentially dissuade a decision 
to undergo chemotherapy. The recommendation of cytotoxic drugs for treatment of 
cancer requires an attention to detail and a holistic approach that encompasses all the 
potential physical harm of the treatment before the first dose is administered. If a breast 
cancer patient realizes she is consuming drugs that have a risk for a loss in vision, she 
may reconsider the end result of her chemotherapy prescription and opt for an alternative 
approach (Schmid, Kornek, Scheithauer & Binder, 2006). 
 In an ideal medical environment, oncologists would work closely with each 
medical profession, including the ophthalmologist, and cover the entire spectrum of 
potential obstacles when treating a breast cancer patient. However, physicians do not 
have the time, or the capabilities, to converse with every single player on a patient’s 
healthcare team. In view of this reality, it is thus even more critical that oncologists 
develop a wide scope of knowledge of the visual symptoms of the chemotherapeutic 
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drugs they prescribe, and work closely with the patient recipient of the cytotoxic 
treatment to ensure that their needs are the number on priority.  
Visual deformities, as a result of cytotoxic medication, will often progress slowly 
and subtlety. Patients will report ocular disturbances when they have grown to be a 
nuisance, but by that time the chemotherapy has usually caused serious damage. At first, 
the clinician and breast cancer patient may find it difficult to detect many of these ocular 
toxicities. However, if the symptoms are not recognized early, the optic damage may 
have progressed to the point of becoming irreversible (Schmid et al., 2006).  
Further research has been performed to evaluate optic nerve and retinal changes in 
patients exposed to high dose chemotherapy. The American Journal of Medical Sciences 
published the research of Dr. Preston Blomquist, who observed that ocular toxicity is 
seen in up to 25% of patients who have undergone a high-dose intravenous therapy using 
the chemotherapeutic agent methotrexate (Blomquist, 2011). Periorbital edema, orbital 
pain, blurred vision, photophobia, and conjunctivitis were all taken into account under the 
definition of ocular toxicity. Blomquist’s metanalysis found that at the culmination of 
chemotherapy varying degrees of vision loss and microvascular lesions on the optic disc 
and retina indicated widespread ocular toxicity potentiated by a high dose regimen. Noted 
side effects included flashes of light across the visual field caused by paclitaxel and 
docetaxel, retinal hemorrhages due to interferon therapy, and keratopathy as a result of an 
aggressive tamoxifen regimen. In light of his research he concluded, “Ocular toxicity is 
common at high dosages,” and “the risk of toxicity is much lower with low-dose 
treatment” (Blomquist, 2011, p. 65). 
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For patients receiving combination or single-agent chemotherapy it is felt that 
ocular toxicity may occur with more intensive regimens, otherwise noted as high dose 
chemotherapy. Chemotherapeutic drugs from all classifications induced ocular toxicities. 
Noted opthalmic symptoms of cyclophosphamide included blurred vision, 
keratoconjunctivitis sicca, pinpoint pupils, and blepharcoconjunctivitis. Cisplatin was 
connected to papilledema, optic neuritis, color blindness, and cortical blindness. 
Injections of 5-fluorouracil produced a host of negative symptoms: blurred vision, ocular 
pain, circumorbital edema, and irritative conjunctivitis comprised only part of the list. In 
review, the presence of optic effects subsequent to high dose chemotherapy may play a 
role in the development of an oncological preference geared toward metronomic 
chemotherapeutic administration (Wickremasinghe, Dansingani, Tranos, Davey, 
Liyanage & Jones, 2007). 
The Adjuvant Potential of Low Dose Chemotherapy 
 The compatibility of low dose chemotherapy, in relation to adjunctive agents, 
must be established if it is to act as a contributing factor in the realm of oncological 
treatment. Scientific dialogue surrounding the use of insulin in potentiating the effects of 
chemotherapy foresees that lower doses of cytotoxic drugs, when coupled with insulin 
administration, may be effective in fighting breast cancer. This hypothesis, though still 
fresh in the research field, may prove to establish itself as more than optimism if fostered 
through further scientific understanding. 
Insulin Potentiated Chemotherapy 
Surprisingly, the role of insulin in the transportation of chemotherapeutic agents 
intracellularly may be a contributing factor in treating breast cancer malignancies. Those 
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in support of Insulin Potentiation Therapy maintain that administering insulin along with 
low doses of chemotherapy helps to promote the uptake of the cytotoxic drugs by tumors. 
Their research suggests that because a greater percentage of the chemotherapeutic drugs 
are engulfed by the tumor, less of the anti-cancer drugs are needed to ensure malignancy 
destruction (Damyanov, Radoslavova,  Gavrilov & Stoeva, 2009).  
It is important to note the effects insulin has on healthy cells that led scientists to 
research its value in fighting cancer. Advocates of Insulin Potentiated Therapy believe 
that cancer cells are more sensitive to insulin because they consume more glucose than 
normal cells (Memorial Sloan-Kettering Cancer Center, 2011). Insulin increases cell 
membrane permeability and facilitates the movement of particles and toxins across the 
semipermeable membrane. It also, “Influences the metabolic processes with a number of 
physicochemical changes which help the recuperating processes” (Damyanov et al., 
2009, p. 712). Simply stated, insulin has the ability to carry multiple biological factors 
into the cell, as well as the ability to alter cellular function in order to ignite the healing 
process. 
The first in-depth study to elaborate in insulin potentiated therapy was cited in 
Clinical Cancer Pharmacology. This research examined the effects of insulin in a 
randomized clinical trial comprised of 30 women with metastatic breast cancer (Lasalvia-
Prisco, Cucchi, Vazquez, Golomar, Lasalvia-Galante & Gordon, 2004). All of the 
patients had measurable lesions that were resistant to flourouracil, adriamycin, 
cyclophosphamide, and hormone therapy.  They found that the hypothesized antitumoral 
effect of methotrexate was supported by their data, and that methotrexate administered 
with insulin produced the greatest benefit in their patients. Those who were given the 
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combination of the two, instead of solely insulin or solely methotrexate, had the lowest 
increase in tumor size and greatest antitumoral influence (Lasalvia-Prisco et al., 2004). 
 Lasalvia-Prisco et al. played a pivotal role in placing insulin potentiated therapy on 
the radar for other oncology researchers (Damyanov et al., 2009). In an article published 
in the Journal of BUON, it was projected that insulin stayed true to its role in normal 
functioning as a carrier of particles when given with chemotherapy. This study theorized 
that the increased permeability of the cancer cell due to insulin administration allows for 
an increase in the levels of the intracellular chemotherapeutic agents (Damyanov et al., 
2009; Memorial Sloan-Kettering Cancer Center, 2011). Insulin also affected the 
metabolism in the tumor cells, thereby increasing the amount of cells that stayed in the S 
phase- a phase during which they are more sensitive to cytotoxic agents. Tumor cells also 
have an increased number of insulin receptors, which make them more susceptible to 
both of these processes and significantly more vulnerable to low doses of chemotherapy 
(Damyanov et al., 2009).  
 The patients who comprised this study were all diagnosed with metastatic 
malignancies that had been unsuccessfully treated with previous regimens. Their 
chemotherapy was well tolerated and the only side effects they identified were weakness 
and sleepiness following their first injections. Their labs showed no toxicity and there 
were minor elevations in their liver enzymes in the first six weeks but they normalized 
“without any addition measures during treatment” (Damyanov et al., 2009, p. 714). 
 Damyanov et al. and Lasalvio-Prisco et al. performed small studies, but the 
evidence formed may prove to have a large impact on the future of chemotherapy. These 
studies advocate for the benefits of a low dose regimen in preference to high doses of 
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chemotherapy, and offer hope of developing alternative approaches in the fight against 
breast malignancy. Further research is required to construct a holistic view of this 
therapy; however, the flexibility of low dose chemotherapy considering its minimal 
toxicity, makes it a prime candidate for adjunctive chemotherapy research. 
Conclusion 
 Women around the world diagnosed with breast cancer are battling every day for 
survival. The effects of high dose chemotherapy have formed a distorted picture of the 
necessity for a decreased quality of life in order to insure cancer remission. The evidence 
supporting low dose chemotherapy and its efficacy may potentially act as an answer for 
women who desire to hold the upper hand in their fight against cancer, while continuing 
to perform activities of their daily life. 
 The allure of low dose chemotherapy is in large part due to its antiangiogenic basis.  
Those in favor of metronomic chemotherapy administration propose this regimen 
combats breast malignancies at their foundation by impeding the tumor microvasculature. 
The inability of a tumor to create vessels cuts off its nutrition supply and restricts further 
metastasis. Vascular endothelial growth factor has also been targeted as a key factor in 
tumor angiogenesis. Low doses of chemotherapeutic agents decrease the release of this 
polypeptide and halt the endothelial growth that forms the tumor blood vessels. This 
physiologic finding, if nurtured through future scientific research, may establish low dose 
chemotherapy as an effective, yet conservative, breast cancer therapy. 
 Reduced dosages of chemotherapy may improve the breast cancer patient’s quality 
of life by limiting the probability of serious side effects. Studies propose that a low dose 
regimen has been linked with decreased cardiotoxicity, maintenance of cognitive 
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functioning, and lesser optic destruction. A diminished symptomatic reaction to 
chemotherapy increases the affected breast cancer patient’s ability to thrive. 
 Low doses of chemotherapy demonstrate increased compatibility and the ability to 
combine with other therapies in order to potentiate the effects of the cytotoxic drugs. 
With additional research, insulin may be proven to maximize the therapeutic benefit of 
chemotherapy and limit the destruction of cytotoxic drugs on healthy cells. The perceived 
benefits of insulin potentiated therapy inspire inquisition regarding advances in adjuvant 
treatments that use low dose chemotherapy, and may indicate the future of conservative 
chemotherapy dosing.  
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